Hyperresponsiveness of the Mucosal Barrier in Crohnʼs Disease Is Not Tumor Necrosis Factor-Dependent

Abstract

Although anti-TNF treatment suppresses inflammation and restores gut barrier function in patients with CD, it does not antagonize the barrier hyperresponsiveness to indomethacin. These data support the notion of an underlying intestinal mucosal barrier hyperresponsiveness in a subset of patients with CD, independent of inflammation.